Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $11.60.

Several brokerages have commented on ZURA. Wall Street Zen downgraded shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Leerink Partners raised Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. Wedbush assumed coverage on shares of Zura Bio in a research note on Monday, February 9th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, Chardan Capital reissued a “buy” rating and issued a $10.00 price target on shares of Zura Bio in a research note on Friday, November 14th.

Institutional Investors Weigh In On Zura Bio

A number of large investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd purchased a new position in shares of Zura Bio in the 2nd quarter worth about $113,000. Alberta Investment Management Corp bought a new stake in shares of Zura Bio in the 2nd quarter valued at about $140,000. Savant Capital LLC grew its position in Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after acquiring an additional 21,249 shares during the last quarter. Millennium Management LLC increased its stake in Zura Bio by 75.1% in the 4th quarter. Millennium Management LLC now owns 1,032,680 shares of the company’s stock worth $5,411,000 after purchasing an additional 442,980 shares during the period. Finally, Barclays PLC lifted its position in Zura Bio by 2,432,950.0% in the fourth quarter. Barclays PLC now owns 48,661 shares of the company’s stock valued at $255,000 after purchasing an additional 48,659 shares during the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Down 1.3%

Shares of NASDAQ ZURA opened at $6.20 on Monday. The business has a 50-day simple moving average of $5.43 and a two-hundred day simple moving average of $3.89. Zura Bio has a 52 week low of $0.97 and a 52 week high of $6.88. The company has a market cap of $403.12 million, a P/E ratio of -9.54 and a beta of 0.21.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.